---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-003931"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T10:04:39.637486+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics Q3 2021 net loss $10.0M; CP101 Phase 2 shows 80.3% cure rate

## Summary
- Net loss of $10.0M for Q3 2021 (vs. $10.1M loss in Q3 2020); R&D expenses increased to $15.5M from $9.0M.
- CP101 Phase 2 open-label trial: 80.3% sustained clinical cure at 8 weeks, 78.8% at 24 weeks in recurrent CDI.
- Initiated enrollment in PRISM4 Phase 3 trial of CP101; topline data expected H1 2023.
- Cash and equivalents $149.2M as of Sept 30, 2021; expected to fund operations into mid-2023.
- CMO Zain Kassam stepped down; Debra Silberg named interim CMO; Marc Blaustein joined as COO; Al Hamood added to board.

## SEC filing metadata
- accession: 0000950170-21-003931
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017021003931/0000950170-21-003931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017021003931/fnch-20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-003931
- JSON: https://secwatch.observer/filing/0000950170-21-003931.json
- Plain text: https://secwatch.observer/filing/0000950170-21-003931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.